Acorah Software Products - Accounts Production 16.5.460 false true false true No description of principal activity 2 January 2024 31 January 2025 31 January 2025 15381534 Mr Lawrence Macmillan iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15381534 2024-01-01 15381534 2025-01-31 15381534 2024-01-02 2025-01-31 15381534 frs-core:CurrentFinancialInstruments 2025-01-31 15381534 frs-bus:PrivateLimitedCompanyLtd 2024-01-02 2025-01-31 15381534 frs-bus:FilletedAccounts 2024-01-02 2025-01-31 15381534 frs-bus:Micro-entities 2024-01-02 2025-01-31 15381534 frs-bus:AuditExempt-NoAccountantsReport 2024-01-02 2025-01-31 15381534 frs-bus:Director1 2024-01-02 2025-01-31
Registered number: 15381534
Sanare Life Sciences Limited
Financial Statements
For the Period 2 January 2024 to 31 January 2025
Balance Sheet
Registered number: 15381534
31 January 2025
£
Fixed assets 1,600
Current assets 135,803
Creditors: Amounts Falling Due Within One Year (70,812 )
NET CURRENT ASSETS 64,991
TOTAL ASSETS LESS CURRENT LIABILITIES 66,591
NET ASSETS 66,591
CAPITAL AND RESERVES 66,591

Notes

1. General Information
Sanare Life Sciences Limited is a private company, limited by shares, incorporated in England & Wales, registered number 15381534 . The registered office is 167-169,Great Portland Street, Greater London, England, W1W 5PF.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Mr Lawrence Macmillan
Director
16 September 2025